Literature DB >> 14973253

Differential effects of CB1 and opioid agonists on two populations of adult rat dorsal root ganglion neurons.

I A Khasabova1, C Harding-Rose, D A Simone, V S Seybold.   

Abstract

Inhibition of primary afferent neurons contributes to the antihyperalgesic effects of opioid and CB1 receptor agonists. Two bioassays were used to compare the effects of the CB1 receptor agonist CP 55,940 and morphine on dissociated adult rat DRG neurons. Both agonists inhibited the increase in free intracellular Ca2+ concentration evoked by depolarization; however, effects of CP 55,940 occurred primarily in large neurons (cell area, >800 microm2), whereas morphine inhibited the response in smaller neurons. Cotreatment with selective blockers of L-, N-, and P/Q-type voltage-dependent Ca2+ channels indicated that CB1 receptors on DRG neurons couple solely with N-type channels but opioid receptors couple with multiple subtypes. Experiments with selective agonists and antagonists of opioid receptors indicated that mu and delta, but not kappa, receptors contributed to the inhibitory effect of morphine on voltage-dependent Ca2+ influx. Because Ca2+ channels underlie release of transmitters from neurons, the effects of opioid agonists and CP 55,940 on depolarization-evoked release of calcitonin gene-related peptide (CGRP) were compared. Morphine inhibited release through delta receptors but CP 55,940 had no effect. Colocalization of CGRP with delta-opioid but not mu-opioid or CB1 receptor immunoreactivity in superficial laminae of the dorsal horn of the spinal cord was consistent with the data for agonist inhibition of peptide release. Therefore, CB1 and opioid agonists couple with different voltage-dependent Ca2+ channels in different populations of DRG neurons. Furthermore, differences occur in the distribution of receptors between the cell body and terminals of DRG neurons. The complementary action of CB1 and opioid receptor agonists on populations of DRG neurons provides a rationale for their combined use in modulation of somatosensory input to the spinal cord.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14973253      PMCID: PMC6730464          DOI: 10.1523/JNEUROSCI.4298-03.2004

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  36 in total

1.  Characterisation of cannabinoid 1 receptor expression in the perikarya, and peripheral and spinal processes of primary sensory neurons.

Authors:  Gabor Veress; Zoltan Meszar; Dora Muszil; Antonio Avelino; Klara Matesz; Ken Mackie; Istvan Nagy
Journal:  Brain Struct Funct       Date:  2012-05-22       Impact factor: 3.270

2.  Proteomic analysis uncovers novel actions of the neurosecretory protein VGF in nociceptive processing.

Authors:  Maureen S Riedl; Patrick D Braun; Kelley F Kitto; Samuel A Roiko; Lorraine B Anderson; Christopher N Honda; Carolyn A Fairbanks; Lucy Vulchanova
Journal:  J Neurosci       Date:  2009-10-21       Impact factor: 6.167

3.  Histone methyltransferase G9a diminishes expression of cannabinoid CB1 receptors in primary sensory neurons in neuropathic pain.

Authors:  Yi Luo; Jixiang Zhang; Lin Chen; Shao-Rui Chen; Hong Chen; Guangfen Zhang; Hui-Lin Pan
Journal:  J Biol Chem       Date:  2020-02-04       Impact factor: 5.157

Review 4.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

5.  GRK2 Constitutively Governs Peripheral Delta Opioid Receptor Activity.

Authors:  Allison Doyle Brackley; Ruben Gomez; Armen N Akopian; Michael A Henry; Nathaniel A Jeske
Journal:  Cell Rep       Date:  2016-08-25       Impact factor: 9.423

Review 6.  Modulation of pain transmission by G-protein-coupled receptors.

Authors:  Hui-Lin Pan; Zi-Zhen Wu; Hong-Yi Zhou; Shao-Rui Chen; Hong-Mei Zhang; De-Pei Li
Journal:  Pharmacol Ther       Date:  2007-09-22       Impact factor: 12.310

7.  Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior.

Authors:  Sacha A Malin; Derek C Molliver
Journal:  Mol Pain       Date:  2010-04-15       Impact factor: 3.395

8.  Intrathecal administration of Resolvin D1 and E1 decreases hyperalgesia in mice with bone cancer pain: Involvement of endocannabinoid signaling.

Authors:  Iryna A Khasabova; Mikhail Y Golovko; Svetlana A Golovko; Donald A Simone; Sergey G Khasabov
Journal:  Prostaglandins Other Lipid Mediat       Date:  2020-07-31       Impact factor: 3.072

9.  Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation.

Authors:  Carl Potenzieri; Thaddeus S Brink; Cholawat Pacharinsak; Donald A Simone
Journal:  J Neurophysiol       Date:  2008-09-10       Impact factor: 2.714

10.  The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain.

Authors:  M L Uhelski; D M Cain; C Harding-Rose; D A Simone
Journal:  Neuroscience       Date:  2013-05-11       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.